Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$45.20K$45.20K+6,853.8% vs Q2 2022 Net Income$2.06M$2.06MN/M vs Q2 2022 EPS Diluted-$0.01-$0.01N/M vs Q2 2022 Gross Profit$45,200+16,828.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$165,840N/M Margins · derivedGross margin100.0%+58.9 pt vs Q2 2022
Operating margin-2502.9%+274227.7 pt vs Q2 2022
Net margin4565.6%+393201.2 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 21, 2023 · 52 d after period end